Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
ABSTRACTBackground The prognosis for advanced intrahepatic cholangiocarcinoma (iCCA) is poor, and there remains an urgent need to develop efficient systemic therapy. The efficacy of Pembrolizumab immunotherapy combined with lenvatinibin in iCCA is still unclear. The role of Epstein–Barr-virus (EBV)...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Cancer Biology & Therapy |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2024.2338644 |